Lever
Lifestyle
- Regular exercise
- Stress management techniques
- Adequate sleep
Blutwerte · Marker
LH
Luteinisierendes Hormon · Luteinizing Hormone · LH
Hormone — ReproduktionsachseZeitabhängig
- Einheit:
- IU/L
Luteinizing Hormone (LH) quantifies the level of this glycoprotein hormone in the blood, which is involved in regulating the reproductive system.
Reference Ranges
Reference
1–20IU/L
1
20
LowNormalHigh
Reference
Unit · IU/LRanges vary by sex and menstrual cycle phase; typically higher during the LH surge.
Overview
Übersicht
Luteinizing Hormone (LH) is a glycoprotein hormone produced by the anterior pituitary gland. It plays a crucial role in regulating the reproductive system by triggering ovulation and stimulating the production of sex hormones such as testosterone in males and estrogen in females. LH is a key component of the hypothalamic-pituitary-gonadal axis, which controls reproductive function. Clinically, LH is important for diagnosing and managing conditions related to reproductive health. Elevated LH levels can indicate conditions such as polycystic ovary syndrome (PCOS) or primary gonadal failure, while low levels may suggest secondary hypogonadism or pituitary disorders. In the context of athletic performance and biohacking, LH is relevant as it influences testosterone production, which is crucial for muscle growth and recovery. However, manipulating LH levels for performance enhancement should be approached with caution due to potential health risks. Researchers have found that LH levels can be affected by factors such as time of day, fasting status, and assay variability. It is important to consider these confounders when interpreting LH test results, and clinicians should collaborate with laboratory professionals to ensure accurate assessments.
Klinische Bedeutung
Elevated LH levels can indicate conditions such as polycystic ovary syndrome (PCOS) or primary gonadal failure. Reduced LH levels may suggest secondary hypogonadism or pituitary disorders.
Dynamics
Trend Interpretation
Rising Values
Progressively rising LH values may suggest the onset of menopause or primary gonadal failure. Re-test in 4 weeks if outside optimal range.
Falling Values
Progressively falling LH values may indicate pituitary dysfunction or hypothalamic suppression.
Re-test Interval
4 weeks if outside optimal range
Etiology
Causes — High & Low
Cause
Elevated Levels
- Polycystic ovary syndrome
- Primary gonadal failure
- Menopause
- Turner syndrome
- Congenital adrenal hyperplasia
Cause
Low Levels
- Secondary hypogonadism
- Pituitary disorders
- Hypothalamic suppression
- Severe stress
- Malnutrition
Protocol
How to Optimize
Lever
Nutrition
- Balanced diet rich in essential nutrients
- Adequate protein intake
Lever
Supplementation
- Vitamin D
- Zinc
- Omega-3 fatty acids
Note:
Consult a healthcare provider before making significant lifestyle changes, especially if underlying conditions are suspected.
Testing Guidelines
✓Fasting Not Required
🕐Time-Sensitive
LH levels can vary throughout the day; testing should be consistent in timing for comparability.
Testing Frequency
Annually for routine check-ups, more frequently if monitoring reproductive health issues.
Interfering Factors
- Recent intense exercise
- Hormonal medications
- Stress
Related Peptides & Hormones
Follicle Stimulating Hormone
hormoneCorrelated with
Estradiol
hormoneCorrelated with
Open Research Questions
Current research suggests that robust reference intervals for luteinizing hormone (LH) remain incomplete, particularly for diverse populations and clinical contexts. Researchers have not yet established optimal targets for LH in various conditions, such as hormone therapy or anorexia nervosa, where its levels may be confounded by other factors. Unanswered clinical questions include the implications of LH assay variability and the clinical significance of 'invisible LH' in patient management.
39 Research Publications
1,011
Total Citations
25
Human/RCT
4.1
Avg. Influence
2024
Latest
Sort
Filter
01Top
#01
Establishment of detailed reference values for luteinizing hormone, follicle stimulating hormone, estradiol, and progesterone during different phases of the menstrual cycle on the Abbott ARCHITECT analyzer.
HumanInfluence28.0
385
This study established detailed reference values for luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, and progesterone throughout the menstrual cycle. Researchers found significant variations in hormone levels, emphasizing the importance of local reference values for accurate laboratory result interpretation.
02Top
03Top
#03
A possible mechanism of action of danazol and an ethinylestradiol/norgestrel combination used as postcoital contraceptive agents.
Human
64
This study examined the effects of an ethinylestradiol/norgestrel combination and danazol on luteinizing hormone (LH) levels in women seeking postcoital contraception. Researchers found no consistent pattern of alteration in urinary steroids, indicating a heterogeneous effect on ovarian function, and no evidence of early pregnancy in successfully treated cases.
04
#04
Urinary melatonin, LH, oestradiol, progesterone excretion during the menstrual cycle or in women taking oral contraceptives.
HumanInfluence1.0
58
This study measured nocturnal urinary excretion of melatonin, LH, progesterone, and oestradiol in women during their menstrual cycle. Researchers found that melatonin excretion significantly increased during the luteal phase compared to the follicular phase, suggesting a relationship between melatonin and progesterone.
05
#05
Long-term intranasal luteinizing hormone-releasing hormone agonist treatment for contraception in women.
Human
49
06
#06
Laboratory parameters and appetite regulators in patients with anorexia nervosa.
HumanInfluence1.0
37
This study explored laboratory parameters in patients with anorexia nervosa (AN). Researchers observed alterations in levels of luteinizing hormone (LH) and other hormones, highlighting the complexity of laboratory findings in diagnosing AN.
07
#07
Ovulation timing. Concepts and controversies.
ReviewInfluence2.0
31
Researchers examined the role of the luteinizing hormone (LH) surge in predicting ovulation timing in dogs. The study highlighted the development of in-clinic assays that allow for accurate identification of the LH surge, improving ovulation prediction in veterinary practice.
08
#08
Basal serum luteinizing hormone value as the screening biomarker in female central precocious puberty.
HumanInfluence4.0
30
Researchers evaluated basal serum LH levels as a screening biomarker for central precocious puberty (CPP) in girls. They found that basal LH was the most sensitive marker for identifying CPP, with specific cutoff values for different age groups. The study highlights the potential for LH levels in early diagnosis.
09
#09
Monitor of chemotherapy in gestational trophoblastic neoplasm by radioimmunoassay of the beta-subunit of human chorionic gonadotropin.
Human
29
Researchers developed an assay based on the beta-subunit of human chorionic gonadotropin (HCG) to monitor patients undergoing chemotherapy for gestational trophoblastic disease. They found that this assay could differentiate tumor activity from normal pituitary LH levels, aiding in treatment decisions.
10
#10
A Comprehensive Review of Estradiol, Progesterone, Luteinizing Hormone, and Follicle-Stimulating Hormone in the Context of Laboratory Medicine to Support Women's Health.
ReviewInfluence2.0
26
This study reviewed the roles of estradiol, progesterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) in women's health. Researchers found that reference intervals for these hormones are incomplete, and collaborative efforts are needed to better define therapeutic or reference intervals to support women's health.
Clinical Trials (10)
10
Total Trials
20,777
Total Enrolled
Evaluation of the Role of Luteinizing Hormone (LH) and Human Chorionic Gonadotropin (hCG) in Adult Patients Undergoing Assessment for Endocrine Disorders
NCT07824102RECRUITING
Sponsor
Martin Blomberg Jensen
Enrollment
20,000
Started
2026
Primary outcome
Association between serum LH and hCG and risk of major osteoporotic fracture (MOF)
OsteoporosisHypercalcemiaPrimary HyperparathyroidismAdrenal Gland DiseasePituitary DiseaseThyroid Diseases
Effects of Adding Quercetin or Alpha Lipoic Acid to Usual Care on Symptoms and Blood Markers in Iraqi Women With Polycystic Ovary Syndrome
Sponsor
Al-Mustansiriyah University
Enrollment
150
Started
2025
Primary outcome
Change in Hormonal Profile (LH, FSH, Testosterone) from Baseline
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
A Study of Andecaliximab in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
Sponsor
Ashibio Inc
Enrollment
92
Started
2024
Primary outcome
Number of New HO Lesions as Assessed by WBCT-LH [Whole body, Computerized Tomography (CT), not including the head (less head)]
Fibrodysplasia Ossificans Progressiva
Quantum Menstrual Health Monitoring Study
NCT05936840RECRUITING
Sponsor
Quanovate Tech Inc.
Enrollment
150
Started
2024
Primary outcome
The rise and fall of urine luteinizing hormone will predict of ovulation in all participants with confirmed ovulation
Menstrual Cycle AbnormalPolycystic Ovary SyndromeAthletes
LH/FSH, Testosterone, Prolactin, and Ferritin in PCOS Patients in Jordan
NCT07112768COMPLETED
Sponsor
Future University in Egypt
Enrollment
140
Started
2024
Primary outcome
Hormonal level
PCOS (Polycystic Ovary Syndrome)
Overcoming Therapy Resistance in ER+ Breast Cancer Patients: a Translational Project (OVERTuRE)
NCT06129786UNKNOWN
Sponsor
Centro di Riferimento Oncologico - Aviano
Enrollment
74
Started
2023
Primary outcome
To identify potential biomarkers predictive of a clinical benefit in patients receiving a first line therapy with AI/fulvestrant (+/- LH-RH analogue) in association with a CDK4/6i for luminal-like ABC.
Breast Cancer
Rec-LH PD and Safety Profile in Hypogonadotropic Hypogonadism Men
Sponsor
Azienda Ospedaliero-Universitaria di Modena
Enrollment
32
Started
2022
Primary outcome
Testosterone
Acquired Hypogonadotropic Hypogonadism
Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome
NCT02705014UNKNOWN
Sponsor
Peking Union Medical College Hospital
Enrollment
20
Started
2016
Primary outcome
Change of serum Luteinizing Hormone(LH) value
Hypogonadotropic Hypogonadism
Effect of Ovarian Stimulation With r-hLH/r-hFSH,r-hFSH and hMG in Reducing Apoptosis Rate in Cumulus Cells of Patients Undergoing ICSI
NCT01872247COMPLETED
Sponsor
Centro di Biologia della Riproduzione, Palermo, Italy
Enrollment
61
Started
2012
Primary outcome
apoptosis of cumulus cell
Infertility
Pharmacodynamics of Lorelin Depot (Leuprorelin Acetate - Bergamo) Compared to Lupron Depot ® (Leuprorelin Acetate - Abbot)
Sponsor
Azidus Brasil
Enrollment
58
Started
2010
Primary outcome
Decrease of serum levels of luteinizing hormone, Testosterone and FSH
Healthy
Publication Trend
Research publications about LH over time
9totalTrack your bloodwork in PepStack
Log lab results, track trends and optimize your biomarkers over time.
Legal Disclaimer
This page is for informational and research purposes only. All information is based on published scientific literature and does not constitute medical advice, diagnosis, or treatment recommendations. Many substances listed may not be approved for human use and may be subject to drug regulation laws (e.g., AMG in Germany, FDA in the US). PepStack does not encourage the use of any substance on humans. Always consult a qualified healthcare professional before making any health-related decisions. Use of this information is entirely at your own risk. PepStack assumes no liability for the accuracy, completeness, or timeliness of the content provided. Full disclaimer